© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Polyinosinic-Polycytidylic Acid, widely recognized as poly(I:C), emerged out of the search for synthetic analogs capable of imitating the body’s natural viral defenses. Early research in the 1960s traced its roots in biochemistry labs, as scientists explored nucleic acid structures that could prompt the immune response. This compound—built from inosinic and cytidylic acid units—attracted attention due to its double-stranded RNA mimicking properties, which resemble viral genetic material. Poly(I:C) didn’t just stay in test tubes; its journey reflects the arc of molecular biology, evolving from a curiosity to a tool for studying immune signaling, antiviral mechanisms, and beyond.
Suppliers offer poly(I:C) as a synthetic analog of double-stranded RNA. The compound typically appears as a white to off-white powder, sometimes a lyophilized cake. Researchers pick poly(I:C) for its stability and solubility in aqueous buffers like phosphate-buffered saline, and because it resists rapid degradation when handled correctly. Products come in grades from research to clinical, depending on purity, endotoxin levels, and preparation standards. The compound’s broad use in immunological research and as an adjuvant in vaccine studies places it at the intersection of molecular biology and medical science.
Poly(I:C) features a repeating motif of inosinic and cytidylic acid residues, linked by phosphodiester bonds. With an average molecular weight ranging from 150–300 kDa, the polymer length varies from batch to batch. The powder absorbs water readily, dissolving in buffer to form viscous solutions, which sometimes require pre-warming for full dissolution. This synthetic molecule carries a negative charge, befitting its nucleic acid backbone, and forms a stable double helix under physiological conditions. Absorption maxima settle around 260 nm—a telltale sign of nucleic acid structure.
Manufacturers present detailed labeling, ensuring traceability and safe handling. Typical labels specify polymer length, molecular weight range, batch number, storage recommendations, and endotoxin levels. Pure poly(I:C) should meet stringent thresholds, with DNAse/RNase-free certification and controlled pyrogen content. Purity sits at or above 98%, minimizing any confusion with similar nucleic acids and ensuring experimental consistency. Lyophilized preparations carry clear expiry dates, with secure vials to prevent degradation from moisture and light.
Synthesis involves template-driven enzymatic or chemical polymerization, starting with activated nucleotides—inosine and cytidine monophosphates. Controlled reaction cycles shape the average chain length. Post-synthesis, the blend gets denatured and annealed, driving the two complementary strands together to form the signature double-stranded structure. Once purified, lyophilization locks in stability for long-term storage. Practically, this method demands clean benches, RNase-free conditions, and acute attention to cross-contamination, mirroring practices honed by decades in the molecular biology field.
Poly(I:C) invites chemical tweaking for advanced applications. Researchers often conjugate poly(I:C) with carriers like polyethylene glycol (PEG), or tag it with fluorescent molecules, streamlining tracking during cellular uptake studies. Cross-linking or grafting onto delivery platforms improves cellular targeting and uptake, expanding its relevance for gene therapy and vaccine development. Dephosphorylation, carboxymethylation, and backbone modifications alter its immunostimulatory strength and in-vivo half-life, making this compound a flexible agent in biotechnological research.
Polyinosinic-Polycytidylic Acid arrives under various guises. Its common shorthand, poly(I:C), remains the go-to for scientists. Some catalogs specify high molecular weight (HMW) or low molecular weight (LMW) poly(I:C), reflecting length variability. Product names include Poly I:C, Polyinosinic:polycytidylic acid, and synthetic dsRNA. Trade names sometimes appear, depending on the formulation or vendor.
Handling poly(I:C) calls for compliance with standard biosafety protocols. Resuspension and aliquoting must occur in designated, RNase-free zones to fend off degradation. Personal protective equipment—masks, gowns, gloves—protects against inadvertent exposure, especially at scales used in clinical or animal studies. Poly(I:C) powders can kick up dust that irritates the mucous membranes; work in fume hoods prevents inhalation. Waste disposal follows local regulations for synthetic nucleic acids, guarding both researchers and the environment.
No discussion of poly(I:C) skips over its role as a viral mimic. It rouses the innate immune system, binding to Toll-like receptor 3 (TLR3) and kicking off cascades that release interferons and inflammatory cytokines. Immunologists spike cultures with poly(I:C) to study antiviral responses or to prime immune cells prior to viral challenge. Cancer researchers inject it as an adjuvant, hoping to turn the body’s defenses against tumors. Poly(I:C) sits at the core of vaccine adjuvant trials, signaling a path forward in immune therapy. Preclinical models tie its use to newer RNA therapeutics, reflecting the shift toward personalized treatments.
Decades of research transformed poly(I:C) from a lab curiosity to a mainstay of immunological investigations. Publications count in the thousands, from early interferon studies to cutting-edge vaccine platforms. Teams now develop modified poly(I:C) derivatives that slip through cellular barriers with improved efficiency, curbing the dose-limiting toxicities. Advanced formulations stack up in clinical pipelines, especially in cancer immunotherapy and viral vaccine development. Collaboration between academic labs, biotech firms, and pharmaceutical giants underscores poly(I:C)’s central role in translational medicine.
Animal studies in the past revealed dose-dependent toxicities. High systemic doses of poly(I:C) generated robust cytokine storms—hyper-inflammatory states echoing severe viral infection. Mice challenged with excessive poly(I:C) display symptoms of fever, malaise, and organ dysfunction. Careful titration selects sub-toxic doses that balance immune activation with safety, and much of current research aims to shield healthy tissue during experimental and therapeutic use. Researchers now investigate delivery vehicles—liposomes, nanoparticles—to rein in adverse immune reactions and steer poly(I:C) directly to its intended cellular targets.
Looking forward, poly(I:C) seems set to influence the next wave of immunotherapies. Its record as a potent adjuvant, plus the versatility offered by polymer modifications, opens doors in cancer vaccine pipelines and engineered T-cell therapies. The explosion of RNA-based medicines draws heavily from lessons learned with poly(I:C). Newer products leverage site-specific conjugation, precision delivery systems, and computational biology to tailor responses at the patient level. Safety remains front-of-mind, catalyzing continuous improvements in design, formulation, and clinical guidelines. Poly(I:C) lives at the intersection of big data, immunology, and chemical engineering, poised to drive medical innovation for decades to come.
Polyinosinic-polycytidylic acid—often called Poly I:C—gets scientists excited because it tricks the body’s immune system into thinking a virus has arrived. Poly I:C looks like double-stranded RNA, the kind you’d spot in many actual viruses, not in healthy people. My own experience as a biology student handed me flashes of the lab bench: adding Poly I:C to cell cultures, antibodies lighting up like signal flares. This synthetic strand tells immune cells to wake up and fight.
Researchers use Poly I:C as a tool to simulate viral infection in animal models and petri dishes. The cells start firing up defense systems, like producing interferons and other messengers. These are crucial for studying how the body responds to real viral threats. If you want to dig into autoimmune disorders, viral immunity, or inflammation, Poly I:C sits at the center of the action. Data published in Nature Immunology and the Journal of Immunology repeat this point—Poly I:C triggers immune pathways needed for strong defense, but also unpacks hidden vulnerabilities when the immune system overreacts.
In vaccine labs, scientists turn to Poly I:C as an adjuvant—something they mix with vaccines to boost the immune system’s wake-up call. This approach can shape research into new vaccines for flu, cancer, or emerging pandemics. The results can be dramatic: animals given vaccines with Poly I:C build robust, precise responses, improving the odds against stubborn diseases. No method works perfectly across all conditions, but Poly I:C often helps the body remember the invaders it faces.
Cancer specialists test Poly I:C to wake up immune cells that might otherwise ignore tumors. Tumors often hide from detection, dampening the immune response. Poly I:C, used with checkpoint inhibitors or as part of experimental therapies, can prod the body into spotting and fighting cancer. I’ve read about patients enrolled in trials where Poly I:C combinations nudged their own immune cells out of lethargy, making treatment more effective.
Despite the positive buzz, Poly I:C deserves respect. Overstimulating the immune system carries real risks. Reports from clinical trials show it can kick off fever and inflammation strong enough to endanger health. Chronic injection in animal models sometimes causes symptoms mimicking autoimmune diseases or viral infections. Experts from the CDC and WHO highlight the need for careful monitoring and strict clinical protocols.
If you ask why Poly I:C gets this kind of attention, it comes down to its power. It reaches across fields, from basic immunology to cancer and vaccine development. Work continues to narrow its targeting, reduce serious side effects, and maximize its benefits. My biggest takeaway: well-understood tools like Poly I:C can teach researchers how to sharpen future therapies, while patient safety and strong oversight keep everyone grounded.
I’ve worked alongside researchers who treat their reagents better than their tools or even their laptops. Poly I:C, as everyone in the lab calls it, ranks high up as an immune system stimulator. This synthetic double-stranded RNA can flip the switch on immune cells, so keeping it in top condition shapes the outcome of countless experiments. If someone fumbles storage, data doesn’t just wobble—it sometimes collapses.
Poly I:C isn’t sugar or salt. Leaving it out on a bench at room temperature will send researchers straight to troubleshooting forums. It’s all about temperature control. At -20°C, this RNA mimic holds its structure and function. If someone expects a vial to last through a long study, a frost-free deep freezer changes the game. Frost-free cycles, meant to save electricity, bring temperature swings. Poly I:C hates those jumps. Regular cold, without all the automated defrosting, keeps the stuff stable and ready to use.
You add water, Poly I:C dissolves, but then the countdown begins. Aqueous solutions don't play nice with time. Microbes grow, nucleases creep in, and degradation follows. For every week it sits above -70°C, activity slips. Fresh prep works for small projects. Bigger runs? Store in tiny aliquots, keep the rest frozen solid and only thaw what’s needed. Those who have seen a gel with smeared RNA know: refreezing after repeated thaws brings trouble no buffer can fix.
Fluorescent bulbs and even daylight can chip away at nucleic acids. Poly I:C gets cranky if it soaks up too much light, especially short wavelengths. Opaque boxes or foil-wrapped tubes get used in every savvy lab. Once I left a rack by the window for just a day—half the sample lost its punch.
It sounds obvious, but labeling beats memory every time. I’ve grabbed vials thinking they’re pristine, only to realize those went through a freeze-thaw-fumble the month before. Label each aliquot with a date and number of thaws. That two-minute step dodges weeks of head-scratching next quarter.
Vendors offer fancy labels about “RNase-Free” vials and “molecular grade” water. That matters, but in day-to-day research, human error sinks more projects than bad suppliers. Regularly clean the ice box. Make stocks in an RNase-free space, and use gloves. Don’t pipette into stock solutions more than needed. These habits look simple, but trust me, mishaps pile up if ignored.
Some labs invest in warning alarms for freezers, temperature tracking, and backup generators. For smaller outfits, splitting stocks and using insulated coolers for daily use make sense. Sharing best practices helps more than expensive gear. A five-minute team talk each semester about storage mistakes can save thousands in wasted reagents and lost data.
Science rarely moves faster than its slowest step. Careful storage of polyinosinic-polycytidylic acid isn’t about red tape—it's about protecting results and dollars. Put the time in up front, and progress won’t stumble on basics gone wrong.
Polyinosinic-polycytidylic acid, often called Poly I:C, pulls attention among researchers studying viruses, cancer, and even vaccine development. This synthetic molecule mimics double-stranded viral RNA and kicks the immune system into high gear. Back in undergrad days, my immunology professor used Poly I:C as an example of a tool that “tricks” the body into thinking a viral threat has landed. Lab work showed its power: cell cultures would light up with immune signals after exposure. That’s what makes it useful—and also what sets up a host of potential side effects.
Anyone who’s had the flu remembers the fatigue, muscle aches, and fever. Poly I:C can bring out similar symptoms. It pushes the body to produce cytokines—chemical messengers like interferons and interleukins. This process spells trouble over time or in high doses. Studies and reports on Poly I:C remind me of spending a night near a sick friend. You end up feeling wiped out, too. People describe chills, headaches, and joint pain. These symptoms aren’t just theoretical; they’re the body’s way of calling for an all-hands-on-deck immune response.
Lab mice injected with Poly I:C show elevated temperature, lethargy, and reduced appetite. Human trials, such as early cancer immunotherapy experiments, backed this up. Volunteers came away with fever, shivering, and a general sick feeling. While most symptoms fade with time or proper support, they underline a reality: anything that charges up immunity can take a toll.
I’ve seen researchers worry that pushing the immune system too hard could do more harm than good. Poly I:C’s strong stimulation can, in rare cases, throw the body off balance. This overreaction can resemble what happens in autoimmune diseases, where healthy tissue gets caught in the crossfire. Some studies found increased risk of inflammatory damage, including swelling in organs such as the liver or brain. It’s hard not to remember stories about friends with lupus or rheumatoid arthritis, where the body becomes its own worst enemy.
People with a history of immune disorders face greater risks. Poly I:C can, at least in theory, light up immune cells to attack healthy organs. The strong reaction might even worsen pre-existing conditions. For these folks, new treatments demand careful planning and a close watch for early signs of trouble.
Besides obvious symptoms, Poly I:C sometimes causes gastrointestinal upset, including nausea and vomiting. These tend to pass, but patients might also see changes in blood markers indicating liver or kidney strain. One animal study caught my eye years ago because the researchers saw mild, temporary changes in liver enzymes. These markers returned to normal, but the incident pushed them to recommend liver tests when giving Poly I:C in clinical settings.
Everyone in medical research feels the pull to push boundaries, but Poly I:C’s strengths call for caution. The excitement around triggering powerful immune responses must balance real risks of inflammation and autoimmune flare-ups. Monitoring, starting with low doses, and keeping a close eye on people with immune challenges can make a difference. Pharmacologists keep exploring smaller, more targeted Poly I:C formulations. The hope is to get the benefits without landing patients in a hospital bed with immune side effects. Finding that sweet spot could take time, but the conversations and stories from early trials offer crucial guideposts for what lies ahead.
Polyinosinic-polycytidylic acid, often shortened to Poly I:C, has been turning heads in labs for decades. This synthetic double-stranded RNA acts as a stand-in for viral genetic material. Scientists use it to mimic how the immune system responds to real infections. For those who spend hours with petri dishes and cell cultures, Poly I:C has become a household name. It pokes the same receptors on immune cells that actual viruses hit, helping us pull back the curtain on human immunity.
Researchers want answers fast, especially when looking to trigger the innate immune response in cells. Poly I:C wakes up toll-like receptor 3 (TLR3) and others, launching a domino effect of signaling that shapes how cells defend themselves. This makes it perfect for asking big questions about inflammation, autoimmune diseases, and how to fine-tune vaccines. In recent years, scientists worldwide have used it to beef up immune reactions, making it valuable for cancer vaccine research and understanding neurological changes brought on by immune triggers. From a practical standpoint, Poly I:C is affordable and stable, so it doesn’t vanish from the shelf in a week or break the bank.
Things change as soon as we start thinking about using Poly I:C in people. Animal studies show it sets off fever, stiff joints, and, on the harsher side, shock or organ damage. During times working in preclinical models, I saw that high doses left mice worn out and frail. That tells us real patients could get too much immune stimulation. Early human trials aiming for cancer immunotherapy ran into barriers with toxicity. Injecting Poly I:C directly led to side effects, so researchers tried breaking the molecule into smaller parts. Poly ICLC (Hiltonol) and Poly IC12U came out of these efforts, offering a softer punch to the immune system. These versions gave hope in early cancer and antiviral trials but called for careful dosing and monitoring.
Other scientists took a different route by loading Poly I:C into nanoparticles or linking it to antibodies. These methods steer the molecule closer to tumor cells or specific immune cells, hoping to hit disease without as many side effects. Evidence from published research in journals like Nature and the Journal of Immunology shows targeted versions reduce toxicity and keep immune responses strong, though larger human trials are still waiting in the wings.
Poly I:C cracked open a door between infectious disease experts, vaccine scientists, and cancer researchers. It reminds us that tweaking the immune response isn’t a game—too much, and the system turns on itself; too little, and disease spreads. My own journey in research taught me that balancing hope with reality guides safe innovation. New Poly I:C versions, careful patient selection, and clever delivery methods look promising. Each step forward leans on common sense and the lessons picked up after early stumbles.
Moving into clinical use means sticking to low doses, testing targeted forms, or combining Poly I:C with other immune modulators for safety. Open data sharing between labs and clinics gives a clear view of side effects and benefits. The message is clear: Poly I:C offers plenty to scientists but asks for respect and care as ambitions grow bigger.
Polyinosinic-polycytidylic acid, or poly I:C, means a lot to researchers who work in immunology or drug development. This synthetic double-stranded RNA sparks interest because it mimics viral infection, flipping on the body’s innate immune machinery. Reading about its progress, I think about the number of times science edges close to an answer, but stops short of clear numbers. That’s exactly what happens around the “recommended dosage” issue. The lab is full of possibilities, but moving from animal trial to clinical use throws up more questions than answers.
Poly I:C stands in as a toll-like receptor (TLR3) agonist. Researchers sprinkle this molecule onto their cell cultures or inject it into mice to pull on the levers of immunity, testing cancer drugs or teaching the body to fend off viral threats. Some early clinical trials toyed with using it as a vaccine adjuvant, especially when new infectious diseases came knocking at the door. Each paper or trial report gives a figure: 1 mg/kg in mice, sometimes as low as 0.1 mg/kg. But compare two studies and you’ll see the numbers sway, sometimes drifting tenfold, all because the species, administration method, or formulation keeps changing.
No drug receives a “recommended dosage” until clinical trials clear the fog. For poly I:C, those trials haven’t turned up enough evidence to guide doctors and pharmacists. The FDA hasn’t handed out an approval stamp for its standard use in humans, so the official dosage remains “experimental.” That means, if someone needs it for research, investigators usually start with the lowest published amount and watch closely for side effects—fever, inflammation, organ stress, often in primates before getting close to a human study.
A story in the lab drove this home for me. A few years ago, I watched a graduate student run into trouble after switching protocols between two poly I:C suppliers. The student kept dosages equal by weight, but missed a key point: molecular weight varies by supplier and lot. A “1 mg/kg” dose in one vial wasn’t equal to “1 mg/kg” from another. Some mice in her study developed strong inflammation, some none at all. She learned the lesson the hard way—clear, evidence-based dosing protects both the people and the science.
The best way to sort this out lies in standardized reporting and more high-quality clinical trials. Lab heads, clinical coordinators, and journal editors all need to put their heads together and demand full disclosure on poly I:C’s source, concentration, injection schedule, and any observed side effects. With this data, systematic reviews can finally connect the dots and build a guidebook for others. Policymakers and funders could back studies that focus less on “do we see an effect?” and more on “what amount gives us benefit without too much risk?”.
Anyone reading about poly I:C for medical treatment needs to keep their guard up. No two situations are alike, and self-experimentation or buying research compounds online doesn’t guarantee safety. Clinical oversight carries real weight. Right now, poly I:C mostly belongs in the lab, not in a clinic’s prescription pad.
Clear dosage recommendations come only after mountains of rigorous testing, open data, and honest discussion of risk. Until that happens, it pays to follow the published evidence, question every step, and trust only what survives full scientific scrutiny. I’ve seen this story play out across dozens of emerging drugs. Poly I:C just happens to be today’s example.
| Names | |
| Preferred IUPAC name | poly[(1→6)-β-D-inosinic acid-co-(1→6)-β-D-cytidylic acid] |
| Other names |
Poly I:C Poly(IC) Polyinosinic-polycytidylic acid sodium salt Polyinosinic-polycytidylic acid potassium salt Polyinosinic-polycytidylic acid sodium Poly Inosinic Polycytidylic Acid |
| Pronunciation | /ˌpɒl.i.aɪˌnɒ.sɪ.nɪk ˌpɒl.iˌsaɪ.tɪˈdɪlɪk ˈæs.ɪd/ |
| Identifiers | |
| CAS Number | [31852-29-6] |
| Beilstein Reference | 3231769 |
| ChEBI | CHEBI:61045 |
| ChEMBL | CHEMBL1201563 |
| ChemSpider | 23867515 |
| DrugBank | DB05517 |
| ECHA InfoCard | 100.271.345 |
| EC Number | 3.1.13.4 |
| Gmelin Reference | 60732 |
| KEGG | C11359 |
| MeSH | D011051 |
| PubChem CID | 86209895 |
| RTECS number | GF8925000 |
| UNII | YC56VK56HI |
| UN number | Not regulated |
| CompTox Dashboard (EPA) | DTXSID8012045 |
| Properties | |
| Chemical formula | (C10H11N5O4)n•(C9H12N3O6)n |
| Molar mass | Variable |
| Appearance | White powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -7.5 |
| Acidity (pKa) | 4.0 |
| Basicity (pKb) | 11.5 |
| Viscosity | Viscous solution |
| Dipole moment | 7.7 D |
| Pharmacology | |
| ATC code | J05AX |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled; may cause an allergic skin reaction. |
| GHS labelling | GHS labelling: Not classified as hazardous according to GHS |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | May cause respiratory irritation. |
| Precautionary statements | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. |
| NFPA 704 (fire diamond) | NFPA 704: 1-1-0 |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous 42 mg/kg |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 30 µg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Poly ICLC Poly IC Poly I:C(12U) rintatolimod |
